Sign In
Buy EDNMY
Edenred Malakoff Unsp Adr Earnings Calls
| Release date | Feb 16, 2026 |
| EPS estimate | - |
| EPS actual | $0.699 |
| Revenue estimate | 831.588M |
| Revenue actual | 1.51B |
| Revenue Surprise | 81.53% |
| Release date | Jul 23, 2025 |
| EPS estimate | - |
| EPS actual | $0.559 |
| Revenue estimate | 846.941M |
| Revenue actual | 1.577B |
| Revenue Surprise | 86.15% |
| Release date | May 07, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Feb 18, 2025 |
| EPS estimate | - |
| EPS actual | $0.587 |
| Revenue estimate | 762.011M |
| Revenue actual | 1.641B |
| Revenue Surprise | 115.38% |
Last 4 Quarters for Edenred Malakoff Unsp Adr
Below you can see how EDNMY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 18, 2025 |
| Price on release | $16.85 |
| EPS estimate | - |
| EPS actual | $0.587 |
| Date | Price |
|---|---|
| Feb 11, 2025 | $16.34 |
| Feb 12, 2025 | $16.50 |
| Feb 13, 2025 | $17.25 |
| Feb 14, 2025 | $17.26 |
| Feb 18, 2025 | $16.85 |
| Feb 19, 2025 | $16.00 |
| Feb 20, 2025 | $16.25 |
| Feb 21, 2025 | $16.30 |
| Feb 24, 2025 | $15.00 |
| 4 days before | 3.12% |
| 4 days after | -10.98% |
| On release day | -5.04% |
| Change in period | -8.20% |
| Release date | May 07, 2025 |
| Price on release | $14.75 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| May 01, 2025 | $15.30 |
| May 02, 2025 | $14.72 |
| May 05, 2025 | $16.00 |
| May 06, 2025 | $15.00 |
| May 07, 2025 | $14.75 |
| May 08, 2025 | $14.73 |
| May 09, 2025 | $15.00 |
| May 12, 2025 | $15.50 |
| May 13, 2025 | $15.60 |
| 4 days before | -3.59% |
| 4 days after | 5.76% |
| On release day | 0% |
| Change in period | 1.96% |
| Release date | Jul 23, 2025 |
| Price on release | $15.85 |
| EPS estimate | - |
| EPS actual | $0.559 |
| Date | Price |
|---|---|
| Jul 17, 2025 | $14.50 |
| Jul 18, 2025 | $15.10 |
| Jul 21, 2025 | $15.35 |
| Jul 22, 2025 | $15.25 |
| Jul 23, 2025 | $15.85 |
| Jul 24, 2025 | $15.45 |
| Jul 25, 2025 | $15.75 |
| Jul 28, 2025 | $15.00 |
| Jul 29, 2025 | $14.75 |
| 4 days before | 9.31% |
| 4 days after | -6.94% |
| On release day | -2.52% |
| Change in period | 1.72% |
| Release date | Feb 16, 2026 |
| Price on release | $10.90 |
| EPS estimate | - |
| EPS actual | $0.699 |
| Date | Price |
|---|---|
| Feb 09, 2026 | $10.35 |
| Feb 10, 2026 | $10.35 |
| Feb 11, 2026 | $10.35 |
| Feb 12, 2026 | $10.95 |
| Feb 13, 2026 | $10.90 |
| Feb 17, 2026 | $10.61 |
| Feb 18, 2026 | $10.40 |
| Feb 19, 2026 | $10.35 |
| Feb 20, 2026 | $10.25 |
| 4 days before | 5.31% |
| 4 days after | -5.96% |
| On release day | -2.66% |
| Change in period | -0.97% |
Edenred Malakoff Unsp Adr Earnings Call Transcript Summary of Q4 2025
Edenred reported strong 2025 results driven by commercial acceleration and operational efficiencies: operating revenue +6.2% like-for-like (9.1% ex‑Italy), EBITDA +11.2% like‑for‑like (c.16% ex‑Italy), adjusted EPS €2.59 (+10%), and very strong free cash flow generation with EBITDA→FCF conversion of 82% (up 12 pts). Management highlighted structural margin expansion (operating EBITDA margin +280 bps to 41.4%) from Fit for Growth actions (workforce efficiency, supplier renegotiations, IT internalization) and reiterated the Amplify strategy focused on “more users, more value per user” (attract, enrich, activate). They will accelerate investments in sales/marketing and data & AI (planned 6x increase in annual data & AI spend) while pursuing platform convergence and portfolio optimization. Capital allocation: dividend proposal €1.33/sh (10% increase vs 2024) and ongoing €300m buyback program (€125m executed in 2025). Net debt fell ~31% to €1.2bn; leverage 0.9x providing balance sheet flexibility for M&A and investment. Key risks: regulatory changes in Italy and a Brazilian presidential decree (legal process ongoing); 2026 is guided as a rebasing year with 2026 EBITDA like‑for‑like guidance of -8% to -12% (worst‑case Brazilian regulatory scenario). Management expects to resume sustainable EBITDA growth of 8–12% like‑for‑like in 2027–2028 and to target €5bn total revenue by 2030.
